VPR Brands, LP will be attending as well as speaking at the 2017 MoneyShow in Orlando

VPR Brands, LP (VPRB) announces First Quarter 2017 Results

|Chart | Calendar   | TRADE NOW | VPRB

VPR Brands, LP announces First Quarter 2017 Results

BUZ INVESTORS  (VPRB) announces First Quarter  VPR Brands, LP (OTC PINK:VPRB) has released its first quarter 2017 results of operations. Revenue for first quarter 2017 totaled $786,535 with a gross profit of $275,014 and a gross margin of 34.96%. In comparison, the first quarter 2016 revenue and gross profit was $-0- and $-0-, respectively. The increase is a result of the asset acquisition from Vapor Corp. of its wholesale business.
Cost of sales for the quarter ended March 31, 2017 and 2016 was $511,521 and $-0-, respectively. The increase is a result of the asset acquisition from Vapor Corp. of its wholesale business.

Operating expenses for the quarter ended March 31, 2017 were $598,556 as compared to $61,005 for the quarter ended March 31, 2016. The increase in expenses is due to increased general, selling and administrative costs for the asset acquisition from Vapor Corp. Payroll made up $250,482 of the difference and marketing expense another $162,330. The rest of the difference included travel expenses and professional fees related to the Vapor Corp. asset acquisition.

Net loss for the quarter ended March 31, 2017 was $(292,294), compared to a net loss of $(61,005) for the quarter ended March 31, 2016. The net loss has increased mainly as the result of the expense related to the increased expenses and interest expense from loans related to the acquisition.

“The Company has completely shifted its focus to service the cannabis sector and is increasing its investment into our award winning HONEYSTICK brand,” said Kevin Frija, CEO of VPR Brands, LP. “We’re excited about our new trajectory and believe that our focus on the HONEYSTICK brand will lead to increased sales of our branded products, which should translate into increased margins and ultimately, profitability.”



(VPRB) announces First Quarter

“The first quarter was a true transitional quarter, where the Company made the switch from distributing popular vaporizer brands and liquids, to building, expanding, and focusing on the HONEYSTICK brand and further expanding its presence in the cannabis space. I believe this transition was in the long term best interest of VPR Brands LP and look forward to the further emergence and expansion of the HONEYSTICK brand as well as our portfolio of cannabis business,” said Dan Hoff, COO of VPR Brands, LP.

Although our sales are not segregated by brand or product category, our primary revenue source is from vaporization devices specifically created for use with medical cannabis and recreational marijuana. These devices are specifically created for use with extract oils and concentrates which are vaped, providing optimal results and the best experience for patients and recreational users. Vaporizers are far more convenient and discrete compared to traditional cannabis use methods. These units are compact, easy to carry and concealable. Modern cannabis vaporizers do not emit distinct and lingering odors that are affiliated with traditional marijuana use. We believe that portable vaporizers are the fastest growing delivery mechanism for marijuana. Our team is currently working with other market leaders within cannabis growth and extraction to innovate and further educate the marketplace on its advantages.

About VPR Brands LP:

VPR Brands is a technology company whose assets include issued U.S. and Chinese patents for atomization related products including technology for medical marijuana vaporizers and electronic cigarette products and components. The Company is also engaged in product development for the vapor or vaping market, including e-liquids, vaporizers and electronic cigarettes (also known as e-cigarettes) which are devices which deliver nicotine and or cannabis through atomization or vaping, and without smoke and other chemical constituents typically found in traditional products. For more information about VPR Brands, please visit the Company on the web at www.vprbrands.com.

bb) Mstart(0)--sm Mstart(0)--md Mstart(33.3%) P(20px) W(1/1)--sm W(1/1)--md ie-7_W(45%)" data-reactid="38">
r) M(a) Maw(600px) Maw(800px)--lg Mih(650px) Mih(0)--sm" data-reactid="39">

bb) Mstart(0)--sm Mstart(0)--md Mstart(33.3%) P(20px) W(1/1)--sm W(1/1)--md ie-7_W(45%)" data-reactid="38">
r) M(a) Maw(600px) Maw(800px)--lg Mih(650px) Mih(0)--sm" data-reactid="39">
r)" data-reactid="2">
bw) Cl(start) Mb(20px) Fz(15px) Lh(1.6) C(#26282a) Ff($ff-secondary) D(i)" data-reactid="10">

Business Description

Industry: Tobacco Products » Tobacco    NAICS: 312230    SIC: 2111
Compare: OTCPK:(GLLA), OTCPK:(SRUP), OTCPK:(VAPI), OTCPK:(RCGR), OTCPK:(NHLE), OTCPK:(BXNG), OTCPK:(MCIG), NYSE:(AOI), NYSE:(TPB), NYSE:(UVV), NYSE:(VGR), OTCPK:(SWMAY), OTCPK:(GGNPF), OTCPK:(IMBBF), OTCPK(:JAPAY), NYSE:(RAI) OTCPK:(BTAFF), NYSE:(MO), NYSE:(PM) » details
Headquarter Location: USA

VPR Brands LP is a technology company. It is engaged in product development for the vapor or vaping market, including e-liquids, vaporizers and electronic cigarettes devices, that delivers nicotine and or cannabis through atomization or vaping.

VPR Brands LP, formerly Soleil Capital LP was incorporated in New York on July 19, 2004, as Jobsinsite.com, Inc. It is engaged in the electronic cigarette and personal vaporizer industry. The Company competes against ” big tobacco”, U.S. cigarette manufacturers of both conventional tobacco cigarettes and electronic cigarettes like Altria Group, Inc., Lorillard, Inc. and Reynolds American, Inc. It competes against ” big tobacco” who offers not only conventional tobacco cigarettes and electronic cigarettes but also smokeless tobacco products such as “snus” (a form of moist ground smokeless tobacco that is usually sold in sachet form that resembles small tea bags), chewing tobacco and snuff. It owns a portfolio of electronic cigarette and personal vaporizer patents.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )



BUZ INVESTORS EDXC Appointment Endexx Corporation ( OTC PINK : EDXC ), a provider of innovative phytonutrient-based food and nutritional products, announced today that the Company has appointed Dr. Daniel Kiddy as Chief Medical

$EDXC Reports Record Sales for the Second Quarter Ended March 31, 2017

|Chart | Calendar   | TRADE NOW | CANNABIS

Endexx Reports Record Sales for the Second Quarter Ended March 31, 2017

 

BUZ INVESTORS PRESS RELEASE  EDXC Reports Record Sales  Endexx Corporation ( OTC PINK : EDXC ), a provider of innovative phyto-nutrient based food and nutritional products, is pleased to report record sales growth for the second quarter of fiscal 2017. For the three months ended March 31, 2017, the Company generated $126K in sales, representing a 47% sequential quarterly increase and a year-over-year revenue growth of 176%.
Second Quarter 2017 Milestones and Updates:

Began mass production of Third Eye Chai, its CBD-Infused Gourmet Tea Beverages with The Mad Hatter Coffee & Tea Co.
Launched its new website Phytobites.com to provide a quick and easy access to drive additional sales channel for Phyto-Bites®, its CBD-infused soft chews for dogs.
Closed on its acquisition of Phyto-Labs LLC to vertically integrate its operations and further develop proprietary formulas for flavored CBD beverages.
CEO Todd Davis was featured on Fox News Phoenix live to speak on Phyto-Bites®.
“We have received a lot of positive reception for Phyto-Bites® and have built an infrastructure to support the growth which we expect to increase substantially in the coming quarters. We are a leader in consumable product lines derived from industrial hemp, which is organic and naturally rich in phytocannabinoids, and are also excited by our CBD-infused gourmet tea ‘Third Eye CBD Chai’, released with our partner The Mad Hatter Coffee and Tea Company. The first production run has completed and has officially launched into sales and delivery. Lastly, we expect a lot of exciting product launches from our Phyto-Labs acquisition. We have recognized that with each new launch, we have seen dramatic sales increases, as our customers are confident in our products,” stated CEO Todd Davis.

EDXC Reports Record Sales

Endexx was recently featured in an NBC News sweeps week special report. The report highlighted Endexx’s approach to the science and education aspect of bringing Cannabidiol and other Phyto-nutrients to the market. The story has generated significant interest in the company. To access the full video please visit: https://www.youtube.com/watch?v=qSXlVK3bCik&feature=youtu.be

The Company is preparing two product launches from Phyto-Labs in late May 2017, as it now has the capability to strategically increase development of its proprietary formulas for nutritional CBD beverages, physician-pharmacist formulated capsules, topical delivery systems and additional pet and livestock products.

About Endexx

Endexx provides innovative inventory management and technology solutions. Endexx, with its collaborative partners and consultants, develops and distributes two consumable product lines derived from industrial hemp, which is organic and naturally rich in phytocannabinoids. Phyto-Bites®, is its CBD-infused soft chews for dogs. The dog treats are formulated to promote health and support the reduction of separation anxiety, pain and inflammation. The company also has two technology products and services that launched in 2014 — the M3hub and the Autospense™. Both products provide essential solutions to promote regulatory compliance and full accountability through “seed to sale” inventory management and an “End of Sale” technology integration. Based on principles developed by the pharmacological industry, the m3hub platform is the first standardized software solution for tracking pharmaceutical grade marijuana that maintains compliance with federal, state and local regulations. It is intended to provide a smooth transition to eventual federal mandates. The Autospense™ is a commercial grade inventory control and dispensing device that provides up-to-the-minute accounting details and ensures both product and patient security. By automating the dispensing process, Autospense™ increases productivity and reduces costs for marijuana retailers, while enhancing their service quality by reducing transaction time for customers. Websites include:www.cbdunlimited.com, www.endexx.com, www.m3hub.com.

Business Description

Industry: Business Services » Business Services    NAICS: 561499    SIC: 7389
Compare: OTCPK:(AEPP), OTCPK:(MVPI), OTCPK:(GEQU), OTCPK:(NNUP), OTCPK:(ITRK), OTCPK:(INVU), OTCPK:(PSCR), OTCPK:(MSNVF), OTCPK:(AWAW), OTCPK:(GBGH), OTCPK:(NAFS), NAS:(SPEX), OTCPK:(MPAY), OTCPK:(PPMT), NAS:(CRTN), OTCPK:(RIHT), OTCPK:(IVFZF), OTCPK:(BMMCF), OTCPK:(YOOIF), OTCPK:9WLKR) » details
Headquarter Location: USA

Endexx Corp is a micro-cap publicly traded company. It is representing the interest of its shareholders and collaborating with software developers, scientists, engineers, and companies to build businesses that can thrive collectively in equity markets.

Endexx Corporation is a micro-cap publicly traded company, representing the interest of its shareholders and collaborating with software developers, scientists, engineers, and companies to build businesses that can thrive collectively in equity markets.

Like up on FACEBOOK EDXC Reports Record Sales


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )

Eurozone GDP rose as expected in 2Q 2016

Eurozone economy expanded 0.5 percent on quarter

|Chart | Calendar   | TRADE NOW | EURUSD

Euro Area GDP Growth Rate  | Data | Chart | Calendar | Forecast

BUZ INVESTORS The Eurozone economy expanded 0.5 percent on quarter in the first three months of 2017, the same as in the previous period and in line with the preliminary estimate. Growth picked up in Germany and Spain but slowed in France and was steady in Italy. GDP Growth Rate in the Euro Area averaged 0.37 percent from 1995 until 2017, reaching an all time high of 1.30 percent in the second quarter of 1997 and a record


low of -3 percent in the first quarter of 2009.

 

 

Eurozone economy expanded


The Eurozone economy expanded 0.5 percent on quarter in the first three months of 2017, the same as in the previous period and in line with the preliminary estimate. Growth picked up in Germany and Spain but slowed in France and was steady in Italy.

Among countries for which data is already available, the GDP expanded at a faster pace in Germany (0.6 percent from 0.4 percent in Q4); Spain (0.8 percent from 0.7 percent in Q4); Belgium (0.5 percent from 0.4 percent); Portugal (1 percent from 0.7 percent); Finland (1.6 percent from 0.3 percent) and Latvia (1.5 percent from 1.2 percent).
Meanwhile, GDP growth slowed in France (0.3 percent from 0.5 percent in Q4); Austria (0.6 percent from 0.5 percent); Netherlands (0.4 percent from 0.6 percent); Cyprus (0.6 percent from 0.7 percent) and Lithuania (1.4 percent from 1.5 percent). In addition, GDP growth was steady in Italy (0.2 percent) and  Slovakia (0.8 percent). The Greek economy contracted for the second quarter (-0.1 percent from -1.2 percent).
Year-on-year, the Euro Area economy expanded 1.7 percent, easing from a 1.8 percent growth in the previous period and in line with earlier estimates.
Considering full European Union, the GDP growth slowed to 0.5 percent from 0.6 percent in Q4, better than initial estimates of 0.4 percent. Annual growth rate was also revised up to 2 percent from 1.9 percent.
Euro Area Markets Last Previous Highest Lowest Unit
Stock Market 3637.52 3623.55 4557.57 1809.98 points [+]
Currency 1.09 1.09 1.87 0.70 [+]
Government Bond 10y -0.45 -0.45 2.57 -0.50 percent [+]

Like up on FACEBOOK


logo



major currencies: (EUR-USD) (USD-JPY) (USD-GBP) (USD-CHF), (USD-CAD), (AUD-USD) (USDCNY)




Terra Tech Announces (OTCQX: TRTC) ("Terra Tech") or (the "Company"), a vertically integrated cannabis-focused agriculture company, today announced that its new Blüm dispensary, located at 1085 South Virginia Street, Reno, Nevada, will open to patients on Monday, January 2nd, 2017 at 9:00 AM Pacific Time

$TRTC Reports First Quarter 2017 Results

|Chart | Calendar   | TRADE NOW |Terra Tech

36px) Fz(25px)--sm Fz(32px) Mb(17px)--sm Mb(20px) Mb(30px)--lg Ff($ff-primary) Lts($lspacing-md) Fw($fweight) Fsm($fsmoothing) Fsmw($fsmoothing) Fsmm($fsmoothing) Wow(bw)" data-reactid="3">Terra Tech Reports First Quarter 2017 Results

Terra Tech Announces (OTCQX: TRTC) ("Terra Tech") or (the "Company"), a vertically integrated cannabis-focused agriculture company, today announced that its new Blüm dispensary, located at 1085 South Virginia Street, Reno, Nevada, will open to patients on Monday, January 2nd, 2017 at 9:00 AM Pacific Time

BUZ INVESTORS PRESS RELEASE  TRTC Reports First Quarter Terra Tech Corp. (TRTC) (“Terra Tech” or the “Company”), a vertically integrated cannabis-focused agriculture

company, today announced its first quarter 2017 financial results for the period ended March 31, 2017.
Derek Peterson, Chief Executive Officer of Terra Tech Corp., commented, “We are pleased to see the impact of our expansion strategy to open cannabis dispensaries in core target markets drive strong sales in the first quarter. We also reported higher sales of our wholesale IVXX-branded cannabis products as a result of its improved brand recognition coupled with expanded distribution channels. Total first quarter revenues were $6.8 million, representing a 340% increase over the prior year period and we are on track to meet our revenue guidance of $38 – $40 million for 2017.”

“This quarter saw the opening of our fourth Nevada-based Blüm dispensary, located in Reno. This location benefits from limited local competition and we are pleased to record excellent initial sales from Blüm, Reno, which was our best-performing dispensary in the quarter. We consider Nevada to be a major growth opportunity for the Company and are proud to have established a strong presence in the State of Nevada, across both Reno and Las Vegas. This week, the Nevada Tax Commission adopted temporary regulations to allow the state to issue recreational marijuana licenses as early as July 1, which should pave the wave for Terra Tech to break into the recreational market in the second half of 2017. This is a source of great excitement for us.”



TRTC Reports First Quarter

>>>TRADE NOW<<<

“Looking ahead, we also remain focused on driving our expansion in the State of California, a major economy with a progressive attitude toward the cannabis sector. To support this strategic goal, we made rapid progress in the first quarter building out a new cultivation facility in Oakland, California, as well as designing both a dispensary and cutting edge production facility in San Leandro, California. We hope to have completed these projects by the end of the year. This was a strong start to the year and we are confident that our strategic growth plan, coupled with ongoing market acceptance of cannabis, will drive Terra Tech’s growth in 2017 and beyond.”

Financial Update:

Total revenues generated for the quarter ended March 31, 2017 increased 340% to approximately $6.8 million, compared to $1.5 million in the same period in 2016. The increase in first quarter revenues was primarily attributable to sales from the Blüm dispensary in Oakland, California, sales from the Company’s four Nevada-based Blüm Dispensaries and sales of IVXX cannabis products. This was partially offset by a decrease in Edible Garden sales due to the expiration of the Company’s contract with a grower of floral products.
Gross profits for the three months ended March 31, 2017 were approximately $359,000, an increase of approximately $225,000 compared with the prior year period. Gross margin for the first quarter of 2017 amounted to approximately 5%, compared to a gross margin of approximately 9% for the first quarter of 2016. Margins were impacted by increased spending on the development of new forms of extracted cannabis products and the refinement of Terra Tech’s propriety recipe of extraction.
Selling, general and administrative expenses for the first quarter of 2017 amounted to approximately $6.4 million, compared to approximately $2.0 million for the first quarter of 2016. The increase was primarily due to an increase in salaries due to new hires associated with the Blüm dispensaries. Other expenses include an increase in consultants’ fees in connection with the Nevada business and an increase in amortization expense due to intangible assets acquired in the Black Oak Gallery acquisition
We realized an operating loss of approximately $6.0 million for the first quarter of 2017, compared to an operating loss of approximately $1.9 million for the first quarter of 2016.
The net loss for the quarter ended March 31, 2017 was approximately $10.1 million or $0.02 per share compared to a loss of approximately $4.1 million or $0.01 per share for the first quarter of 2016.
Stockholders’ equity for the first quarter of 2017 amounted to approximately $49.8 million, compared to approximately $52.2 million as of December 31, 2016.
Short-term debt as of March 31, 2017 amounted to approximately $505,000, compared with approximately $564,000 as of December 31, 2016. Long term debt increased from $1.4 million to $1.7 million during the first three months of 2017, due to additional borrowings used for working capital and capital expenditures.
Business Update:

Cannabis Segment Updates:Opened Blüm, Reno cannabis dispensary to the public on January 2nd, followed by Grand Opening on January 12th.
Completed demolition work and design work for both a dispensary and cutting edge production facility, in addition to a community meeting space, for a dispensary and production facility under construction in San Leandro, California.
Commenced construction of a new cultivation facility in Oakland, California.
Edible Garden Updates:Increased distribution of our Organic Superleaf line at our Northeast supermarkets.
Increased our organic line of products by adding Organic butter head lettuce.
Continue to implement new technology to improve efficiencies, production and margins.
Miscellaneous Operational Updates:Derek Peterson, CEO, participated as a panelist at the California Cannabis Industry Association’s (CCIA) 2nd Annual Policy Conference on March 7th, 2017, and MJIC Media’s 3rd Annual Spring Cannabis Business Expo on March 8th, 2017.
Conference Call

The company will also host a conference call today, Thursday, May 11, 2017 at 9:00 AM Eastern to discuss its financial results and the outlook for 2017.

Dial-In Number: 1-857-232-0157

Access Code: 422095

For those unable to participate in the live conference call, a replay will be available at http://smallcapvoice.com/blog/trtc

An archived version of the webcast will also be available on the investor relations section of the company’s website.

About Terra Tech

Terra Tech Corp. (TRTC) operates through multiple subsidiary businesses including: Blüm, IVXX Inc., Edible Garden, MediFarm LLC and GrowOp Technology. Blüm’s retail medical cannabis facilities focus on providing the highest quality medical cannabis to patients who are looking for alternative treatments for their chronic medical conditions. Blüm offers a broad selection of medical cannabis products including; flowers, concentrates and edibles through its Oakland, CA and multiple Nevada locations. IVXX, Inc. is a wholly-owned subsidiary of Terra Tech that produces medical cannabis-extracted products for regulated medical cannabis dispensaries throughout California. The Company’s wholly-owned subsidiary, Edible Garden, cultivates a premier brand of local and sustainably grown hydroponic produce, sold through major grocery stores such as ShopRite, Walmart, Winn-Dixie, Raley’s, Meijer, Kroger, and others throughout New Jersey, New York, Delaware, Maryland, Connecticut, Pennsylvania and the Midwest. Terra Tech’s MediFarm LLC subsidiaries are focused on medical cannabis cultivation and permitting businesses throughout Nevada. The Company’s wholly-owned subsidiary GrowOp Technology, specializes in controlled environment agricultural technologies.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




BUZ INVESTORS big stock bonuses A year ago, Peabody Energy Corp's BTUUQ.PK chief executive was presiding over $2 billion of losses

Peabody Reports Earnings For Quarter Ended March 31, 2017; Revises Financial Targets For Full-Year 2017

|Chart | Calendar   | TRADE NOW | Peabody Energy

36px) Fz(25px)--sm Fz(32px) Mb(17px)--sm Mb(20px) Mb(30px)--lg Ff($ff-primary) Lts($lspacing-md) Fw($fweight) Fsm($fsmoothing) Fsmw($fsmoothing) Fsmm($fsmoothing) Wow(bw)" data-reactid="3">Peabody Reports Earnings For Quarter Ended March 31, 2017; Revises Financial Targets For Full-Year 2017

BUZ INVESTORS PRESS RELEASE Peabody Reports Earnings Revenue, income from continuing operations net of income taxes, net income, and Adjusted EBITDAR1

BUZ INVESTORS PRESS RELEASE  Peabody Reports Earnings Revenue, income from continuing operations net of income taxes, net income, and Adjusted EBITDAR1 all rise substantially on higher PRB shipments and increased Australian thermal and metallurgical coal pricing; net income reaches highest level in nearly five years; 2017 targets revised to reflect higher met coal volumes from full year of contributions from the Metropolitan hard coking coal mine.

Peabody (BTU) announced today that first quarter 2017 revenues, net income and Adjusted EBITDAR all showed substantial increases over the first quarter of 2016.  Revenues increased 29 percent to $1.33 billion.  Net income attributable to common stockholders increased $287.2 million to $122.1 million, the highest net income in nearly five years, and income from continuing operations net of income taxes rose $292.7 million to $131.0 million.  Adjusted EBITDAR increased $304.9 million to $390.0 million.

Peabody today also revised its full-year financial targets to reflect higher metallurgical coal volumes even in the aftermath of Cyclone Debbie in Australia.  The company is retaining the Metropolitan hard coking coal mine and its associated 16.67 percent interest in Port Kembla Coal Terminal in the company’s portfolio, after proposed purchaser South32 was unable to obtain regulatory clearance and terminated the purchase contract last month.

The company adopted fresh-start accounting under applicable accounting rules as of the April 3, 2017, effective date of the company’s plan of reorganization, which is not reflected in these first quarter results.  The adoption of fresh-start accounting may materially affect its results of operations following the fresh-start reporting dates, as the company will have a new basis in its assets and liabilities.  As a result, certain balance sheet and income statement items will not be comparable to previously reported historical results, including the first quarter 2017 results presented here.

“Peabody’s first quarter results were significantly improved over the prior year across the platform, reflecting sharply higher coal demand in the United States and expanded Australian margins for both thermal and metallurgical coal,” said Peabody President and Chief Executive Officer Glenn Kellow. “Whilst several temporary issues in Australia prevented the quarter from meeting our full potential, our performance was greatly improved with excellent cash generation from our operations.  We look forward to advancing with a strengthened balance sheet, rebounding shipments in Queensland, and retention of the Metropolitan Mine in New South Wales.”




Peabody Reports Earnings

>>>TRADE NOW<<<

4px) My(1.4em) Ov(a) canvas-atom" data-type="table" data-reactid="17">

Note: All comparisons are to first quarter of 2016 unless otherwise noted.

1 Adjusted EBITDAR is a non-GAAP financial measure. Please refer to the tables in this press release for a reconciliation of non-GAAP financial measures. 

First Quarter Results

First quarter revenues rose 29 percent to $1.33 billion (from $1.03 billion in the prior year), driven by a 26 percent increase in Powder River Basin shipments, 17 percent rise in Western sales volumes, and 139 percent and 44 percent average revenue-per-ton increases in Australian metallurgical and thermal coal, respectively.

First quarter 2017 net income attributable to common stockholders increased $287.2 million to $122.1 million, and reflected $93.3 million in lower interest expense associated with the impact of interest under certain debt instruments being stayed during the Chapter 11 proceedings, partly offset by $61.3 million in reduced tax benefits.

Quarterly income from continuing operations net of income taxes increased $292.7 million to $131.0 million, led by a 29 percent increase in revenues that outpaced a 5 percent increase in operating costs and expenses.

First quarter Adjusted EBITDAR rose to $390.0 million, a $304.9 million increase over the first quarter of 2016.  Adjusted EBITDAR included approximately $30 million in negative first quarter impacts from Cyclone Debbie in Australia and a $20 million benefit associated with the sale of the company’s 37.5 percent interest in the Dominion Terminal Associates in Virginia as part of the company’s ongoing portfolio management process.

Within consolidated Adjusted EBITDAR:

    d)" data-type="list" data-reactid="26">
  • U.S. Adjusted EBITDA increased 24 percent to $191.7 million, with improvements led by higher Powder River Basin and Western shipments, partly offset by reduced margins at Midwestern operations and a $13 million benefit related to a contractual resolution with a Southwestern U.S. coal customer.  Sales volumes, revenues per ton and costs per ton were all consistent with the company’s prior annual financial targets.
  • Australian Adjusted EBITDA rose to $185.2 million from $5.6 million in 2016, driven by a 139 percent increase in metallurgical coal revenues to $150.22 per ton, as well as a 44 percent increase in thermal coal revenues to $48.65 per ton.  Operating costs per ton rose 35 percent in Australian metallurgical mining, led by the impacts of Cyclone Debbie, temporary geologic and operating issues at several operations, and increased royalties due to higher prices.
  • Trading and Brokerage Adjusted EBITDA increased to $25.4 million from a loss of ($18.8) million in 2016, benefitting from realized profits on hedge positions taken in prior periods.

“With profitable operations across the U.S. and Australian platforms, Peabody looks forward to generating cash, further reducing debt and returning cash to shareholders over time,” said Peabody Executive Vice President and Chief Financial Officer Amy Schwetz.  “We have a new capital structure and focused capital discipline that is designed to serve shareholders well through all cycles.”

2017 Targets

Sales Volumes (short tons)

Australia Operations – Costs Per Ton (USD)3

PRB

115 – 120 million

Metallurgical

$85 – $95

ILB

18 – 20 million

Thermal

$31 – $35

Total U.S.

145 – 155 million

Total Australia

$51 – $54

Australia Metallurgical1

11 – 12 million

Capital Expenditures

$165 – $195 million

Australia Export Thermal2

13 – 14 million

Australia Domestic Thermal

~8 million

Q2 – Q4 2017 Cost Sensitivities4

Total Australia

32 – 34 million

$0.05 Decrease in A$ FX Rate5

+~$70 – $75 million

$0.05 Increase in A$ FX Rate5

– ~$30 – $35 million

Trading and Brokerage

3 – 7 million

Fuel (+/- $10/barrel)

+/- ~$24 million

Total Tons Sold

180 – 196 million

Priced Position

PRB Tons 

~115 million tons

U.S. Operations – Revenues Per Ton

PRB Average Price/Ton

$12.67

PRB

$12.40 – $12.90  

ILB Tons

~19 million tons

ILB

$41.75 – $43.75  

ILB Average Price/Ton

$42.39

Total U.S.

$18.90 – $19.30  

Essentially all of Peabody’s expected 2017 U.S. production

is priced as of March 31, 2017; 52% of 2018 volumes

are priced and 67% contracted (on a 2017 projected

sales volume basis).

U.S. Operations – Costs Per Ton

PRB

$9.75 – $10.25  

ILB

$31.25 – $33.25  

Total U.S.

$14.50 – $15.00  

Additional notes on following page

Like up on FACEBOOK
Market quotes are powered by
TradingView.com


Commodities ( Gold ) ( Silver ) ( Lithium )




RADCOM (NASDAQ: RDCM) is a first-mover and leading provider of NFV-ready service assurance and Customer Experience Management (

RADCOM Reports Fourth Quarter and Full Year 2016 Financial Results

Chart | Calendar   | TRADE NOW | RDCM

RADCOM Reports Fourth Quarter and Full Year 2016 Financial Results

BUZ INVESTORS RADCOM Reports Fourth Quarter   RADCOM Ltd. <span data-recalc-dims=(RDCM) today reported its financial results for the fourth quarter and fiscal year ended December 31, 2016." width="300" height="103" srcset="https://i2.wp.com/investorsbuz.com/wp-content/uploads/2017/03/download-Small-1.jpg?resize=300%2C103 300w, https://i2.wp.com/investorsbuz.com/wp-content/uploads/2017/03/download-Small-1.jpg?resize=768%2C263 768w, https://i2.wp.com/investorsbuz.com/wp-content/uploads/2017/03/download-Small-1.jpg?w=854 854w" sizes="(max-width: 300px) 100vw, 300px" />

BUZ INVESTORS RADCOM Reports Fourth Quarter   RADCOM Ltd. (RDCM) today reported its financial results for the fourth quarter and fiscal year ended December 31, 2016.

“The fourth quarter marked a strong end to a great year for the Company, highlighted by our ability to reach the high-end of our guidance range,” commented Mr. Yaron Ravkaie, RADCOM’s CEO.  “In 2016, we made great progress with our top-tier customer deployments, continued our engagement with other leading global carriers, and focused on preparing the company for future growth by boosting our senior management team and ramping up our engineering capabilities.  We believe we have laid a solid foundation during 2016 to continue our momentum, as evidenced by our initial 2017 revenue guidance range of $36-$39 million.”

Fourth Quarter 2016 Financial Highlights

  • Revenues: Total revenues for the fourth quarter were $8.0 million, up 196% compared to $2.7 million in the fourth quarter of 2015.
  • Net Loss: GAAP net loss for the period was approximately $0.7 million, or $0.06 loss per diluted share, compared to a loss of $2.1 million, or $0.25 loss per diluted share for the fourth quarter of 2015.
  • Non-GAAP Net Income/(Loss):  Non-GAAP net income for the period was approximately $0.4 million, or $0.04 per diluted share, compared to a loss of $(1.6) million, or $(0.19) per diluted share for the fourth quarter of 2015.Both GAAP and non-GAAP results for the fourth quarter of 2016 included a $552,000, or $0.05 per diluted share, benefit related to grants from the Israel Innovation Authority (formerly Office of the Chief Scientist) compared to $576,000, or $0.07 per diluted share, in the fourth quarter of 2015.
  • Balance sheet: As of December 31, 2016, the Company had cash and cash equivalents of $42.9 million and no debt.




RADCOM Reports Fourth Quarter

>>>>TRADE NOW<<<

Full Year 2016 Financial Highlights

  • Revenues: Total revenues for the full year 2016 were $29.5 million, up 58% compared to $18.7 million in the full year 2015.
  • Net Income/(Loss): GAAP net income for the full year 2016 was approximately $1.9 million, or $0.18 per diluted share, compared to a loss of $(923,000), or $(0.11) per diluted share for the full year 2015.
  • Non-GAAP Net Income:  Non-GAAP net income for the period was approximately $4.8 million or $0.44 per diluted share, for the full year 2016, compared to $656,000, or $0.07 per diluted share for the full year 2015.Both GAAP and non-GAAP results for the full year 2016 included a $1.7 million, or $0.16 per diluted share, benefit related to grants from the Israel Innovation Authority compared to $1.6 million, or $0.18 per diluted share, in 2015.

Earnings Conference Call
RADCOM’s management will hold an interactive conference call today at 8:00 AM Eastern Time (15:00 Israel Time) to discuss the results and to answer participants’ questions. To join the call, please call one of the following numbers approximately five minutes before the call is scheduled to begin:

From the US (toll-free): + 1-888-668-9141

From other locations: +972-3-918-0609

For those unable to listen to the call at the time, a replay will be available from February 15th on RADCOM’s website.

About RADCOM

RADCOM (NASDAQ: RDCM) is a first-mover and leading provider of NFV-ready service assurance and customer experience management solutions for Communications Service Providers (CSPs). RADCOM’s software – MaveriQ – continuously monitors network performance and quality of services, to optimize user experience for CSPs’ subscribers. RADCOM specializes in solutions for next-generation mobile and fixed networks, including LTE, VoLTE, IMS and others. MaveriQ enables CSPs to smoothly migrate their networks to NFV by assuring physical, NFV-based and hybrid networks. For more information, please visit www.radcom.com.

Non-GAAP Information

Certain non-GAAP financial measures are included in this press release. These non-GAAP financial measures are provided to enhance the reader’s overall understanding of the Company’s financial performance. By excluding non-cash stock-based compensation that has been expensed in accordance with ASC Topic 718, inventory write-off and  non-cash write-off of importation taxes, the Company’s non-GAAP results provide information to both management and investors that is useful in assessing the Company’s core operating performance and in evaluating and comparing the Company’s results of operations on a consistent basis from period to period. These non-GAAP financial measures are also used by management to evaluate financial results and to plan and forecast future periods.  The presentation of this additional information is not meant to be considered a substitute for the corresponding financial measures prepared in accordance with GAAP.

Risks Regarding Forward-Looking Statements

Certain statements made herein that use words such as “estimate,” “project,” “intend,” “expect,” “‘believe”, “may”, “might”, “predict”, “potential”, “anticipate”, “plan” or similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. For example, when the Company discusses its momentum and revenue guidance for 2017 it is using foward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that could cause the actual results, performance or achievements of the Company to be materially different from those that may be expressed or implied by such statements, including, among others, changes in general economic and business conditions and specifically, decline in the demand for the Company’s products, inability to timely develop and introduce new technologies, products and applications, and loss of market share and pressure on prices resulting from competition. For additional information regarding these and other risks and uncertainties associated with the Company’s business, reference is made to the Company’s reports filed from time to time with the U.S. Securities and Exchange Commission. The Company does not undertake to revise or update any forward-looking statements for any reason.

 

Like up on FACEBOOK


Ebates Coupons and Cash Back

Market quotes are powered by
TradingView.com



Tech Stocks ( GOOG)   (MSFT ) ( AAPL ) (BBRY ) ( gopro )  ( WDC )




OTHER RELATED STORIES 

BUZ INVESTORS PRESS RELEASE F5 Networks, Inc. (FFIV) today announced revenue of $518.2 million for the second quarter of fiscal 2017, up 7.1% from $483.7 million in the second quarter of fiscal 2016. Growth compared with the second

F5 Networks Announces Second Quarter Fiscal 2017 Results

F5 Networks Announces Second Quarter Fiscal 2017 Results

BUZ INVESTORS PRESS RELEASE F5 Networks, Inc. <span data-recalc-dims=(FFIV) today announced revenue of $518.2 million for the second quarter of fiscal 2017, up 7.1% from $483.7 million in the second quarter of fiscal 2016. Growth compared with the second" width="300" height="200" srcset="https://i0.wp.com/investorsbuz.com/wp-content/uploads/2017/04/F5-Headquarters-1240x827-Small.jpg?resize=300%2C200 300w, https://i0.wp.com/investorsbuz.com/wp-content/uploads/2017/04/F5-Headquarters-1240x827-Small.jpg?w=720 720w" sizes="(max-width: 300px) 100vw, 300px" />

BUZ INVESTORS PRESS RELEASE F5 Networks, Inc. (FFIV) today announced revenue of $518.2 million for the second quarter of fiscal 2017, up 7.1% from $483.7 million in the second quarter of fiscal 2016. Growth compared with the second quarter of fiscal 2016 was driven by solid execution in the Americasand strong sales of security solutions. Partially offsetting these positive trends was continued soft demand in Europe.

GAAP net income for the second quarter of fiscal 2017 was $93.1 million, or $1.43 per diluted share, compared to $75.4 million, or $1.11 per diluted share in the second quarter of 2016. Non-GAAP net income for the second quarter of fiscal 2017 was $127.0 million, or $1.95 per diluted share, compared to $114.0 million, or $1.68 per diluted share in the second quarter of fiscal 2016.

A reconciliation of net income, earnings per share, and other measures on a GAAP to non-GAAP basis is included on the attached Consolidated Income Statements.



F5 Networks

In the just completed quarter, several new products were introduced including 40-Gigabit BIG-IP virtual editions, Herculon SSL Orchestrator and Herculon DDoS Hybrid Defender purpose-built security products, as well as the latest version of our BIG-IP operating system, TMOS 13.0. BIG-IP iSeries products continue to be well received by customers with adoption trends tracking in line with past major product refresh cycles. The BIG-IP iSeries appliance family was architected to offer massive performance and scalability across the entire line, and these programmable, software-defined hardware platforms include features designed to simplify private cloud deployments and hybrid cloud build-outs.

Several new products scheduled to begin shipping in the current quarter are designed to help enable customers to deploy their applications across a variety of cloud environments. These solutions include Application Connector 1.0 for connecting public and private cloud application infrastructures, support for BIG-IP in the Google Public Cloud, and Container Connector and Application Services Proxy for microservices environments.

“My early internal and external interactions have reinforced my enthusiasm for joining the F5 team and my view that the company offers a compelling platform for growth,” said François Locoh-Donou, F5 President and Chief Executive Officer. “I am excited by the new products and services we continue to bring to market and I look forward to actively engaging with our customers and key strategic partners around these offerings.

“With a strong culture of technology innovation and a solid financial foundation, F5 is uniquely positioned to address our customers’ evolving demands around securing and optimizing performance of their mission-critical business applications.”

For the third quarter of fiscal 2017, ending June 30, the company has set a revenue goal of $520 million to $530 million with a GAAP earnings target of $1.47 to $1.50 per diluted share and a non-GAAP earnings target of $2.01 to $2.04 per diluted share.

A reconciliation of the company’s expected GAAP and non-GAAP earnings is provided in the following table:

Three months ended
June 30, 2017
Reconciliation of Expected Non-GAAP Third Quarter Earnings Low High
Net income $ 94.8 $ 96.8
Stock-based compensation expense $ 44.0 $ 44.0
Amortization of purchased intangible assets $ 2.8 $ 2.8
Tax effects related to above items $ (12.1 ) $ (12.1 )
Non-GAAP net income excluding stock-based compensation expense and amortization of purchased intangible assets $ 129.5 $ 131.5
Net income per share – diluted $ 1.47 $ 1.50
Non-GAAP net income per share – diluted $ 2.01 $ 2.04

Like up on FACEBOOK


Ebates Coupons and Cash Back

Market quotes are powered by
TradingView.com



Tech Stocks ( GOOG)   (MSFT ) ( AAPL ) (BBRY ) ( gopro )  ( WDC )




Amgen Reports First Quarter 2017 Financial Results

View printer-friendly version

Amgen Reports First Quarter 2017 Financial Results

BUZ INVESTORS PRESS RELEASE Amgen Reports First Quarter THOUSAND OAKS, Calif., April 26, 2017 /PRNewswire/ -- Amgen <span data-recalc-dims=(NASDAQ:AMGN) today announced financial results for the first quarter of 2017. Key results include:" width="300" height="225" srcset="https://i1.wp.com/investorsbuz.com/wp-content/uploads/2016/11/amgen-stock-300x225.resized-1.jpg?resize=300%2C225 300w, https://i1.wp.com/investorsbuz.com/wp-content/uploads/2016/11/amgen-stock-300x225.resized-1.jpg?w=640 640w" sizes="(max-width: 300px) 100vw, 300px" />

BUZ INVESTORS  PRESS RELEASE  Amgen Reports First Quarter Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2017. Key results include:

  • Total revenues decreased 1 percent versus the first quarter of 2016 to $5.5 billion.
  • GAAP earnings per share (EPS) increased 12 percent to $2.79 driven by higher operating margins.
    • GAAP operating income increased 8 percent to $2.6 billion and GAAP operating margin increased 4 percentage points to 49.8 percent.
  • Non-GAAP EPS increased 9 percent to $3.15 driven by higher operating margins.
    • Non-GAAP operating income increased 5 percent to $3.0 billion and non-GAAP operating margin increased 3 percentage points to 57.6 percent.
  • 2017 EPS guidance increased to $10.64-$11.32 on a GAAP basis and $12.00-$12.60 on a non-GAAP basis; total revenues guidance unchanged at $22.3-$23.1 billion.
  • The Company generated $2.2 billion of free cash flow in the first quarter versus $1.8 billion in the first quarter of 2016.




 Amgen Reports First Quarter

“We are well positioned for the long term with our newer products demonstrating volume growth around the world and our tight operational expense management of the Company,” said Robert A. Bradway, chairman and chief executive officer. “With robust Repatha® (evolocumab) outcomes data, we are working with payers to improve access to this important therapy for patients at risk for heart attacks and strokes.”

$Millions, except EPS and percentages Q1’17 Q1’16 YOY Δ
Total Revenues $ 5,464 $ 5,527 (1%)
GAAP Operating Income $ 2,591 $ 2,402 8%
GAAP Net Income $ 2,071 $ 1,900 9%
GAAP EPS $   2.79 $   2.50 12%
Non-GAAP Operating Income $ 2,995 $ 2,859 5%
Non-GAAP Net Income $ 2,333 $ 2,203 6%
Non-GAAP EPS $   3.15 $   2.90 9%
References in this release to “non-GAAP” measures, measures presented “on a non-GAAP basis” and to “free cash flow” (computed by subtracting capital expenditures from operating cash flow) refer to non-GAAP financial measures. Adjustments to the most directly comparable GAAP financial measures and other items are presented on the attached reconciliations.

Product Sales Performance

  • Total product sales decreased 1 percent for the first quarter of 2017 versus the first quarter of 2016.

  • Neulasta® (pegfilgrastim) sales increased 2 percent as favorable changes in accounting estimates and net selling price were offset partially by lower unit demand.

  • Enbrel® (etanercept) sales decreased 15 percent due to the impact of competition as well as lower rheumatology and dermatology segment growth compared to prior quarters.

  • Aranesp® (darbepoetin alfa) sales decreased 4 percent as higher unit demand was more than offset by unfavorable changes in foreign exchange rates, inventory and net selling price.

  • Prolia® (denosumab) sales increased 21 percent driven by higher unit demand.

  • Sensipar/Mimpara® (cinacalcet) sales increased 15 percent driven primarily by net selling price.

  • XGEVA® (denosumab) sales increased 6 percent driven by higher unit demand.

  • EPOGEN® (epoetin alfa) sales decreased 10 percent driven by net selling price.

  • KYPROLIS® (carfilzomib) sales increased 23 percent driven by higher unit demand.

  • Nplate® (romiplostim) sales increased 9 percent driven by higher unit demand.

  • NEUPOGEN® (filgrastim) sales decreased 31 percent driven primarily by the impact of competition.

  • Vectibix® (panitumumab) sales increased 2 percent driven by higher unit demand, offset partially by unfavorable changes in foreign exchange rates.

  • Repatha sales increased driven by higher unit demand.

  • BLINCYTO® (blinatumomab) sales increased 26 percent driven by higher unit demand.

Product Sales Detail by Product and Geographic Region
$Millions, except percentages Q1’17 Q1’16 YOY Δ
US ROW TOTAL TOTAL TOTAL
Neulasta® $1,048 $162 $1,210 $1,183 2%
Enbrel® 1,118 63 1,181 1,385 (15%)
Aranesp® 278 233 511 532 (4%)
Prolia® 279 146 425 352 21%
Sensipar® / Mimpara® 337 84 421 367 15%
XGEVA® 298 104 402 378 6%
EPOGEN® 270 0 270 300 (10%)
KYPROLIS® 137 53 190 154 23%
Nplate® 97 57 154 141 9%
NEUPOGEN® 101 47 148 213 (31%)
Vectibix® 61 86 147 144 2%
Repatha® 33 16 49 16 *
BLINCYTO® 23 11 34 27 26%
Other** 15 42 57 47 21%
Total product sales $4,095 $1,104 $5,199 $5,239 (1%)
* Change in excess of 100%
** Other includes Bergamo, MN Pharma, IMLYGIC®and Corlanor®

Operating Expense, Operating Margin and Tax Rate Analysis

On a GAAP basis:

  • Total Operating Expenses decreased 8 percent, with all expense categories reflecting savings from our transformation and process improvement efforts. Cost of Sales margin improved by 0.2 percentage points driven primarily by manufacturing efficiencies, offset partially by product mix. Research & Development (R&D) expenses decreased 12 percent driven by a payment in the first quarter of 2016 related to a third-party collaboration agreement, as well as lower spending required to support certain later-stage clinical programs. Selling, General & Administrative (SG&A) expenses decreased 12 percent due to the expiration of ENBREL residual royalty payments and an acquisition charge in the first quarter of 2016, offset partially by investments in product launches.

  • Operating Margin improved by 4 percentage points to 49.8 percent.

  • Tax Rate decreased 0.1 percentage points as changes in the geographic mix of earnings were offset partially by lower tax benefits from share-based compensation payments.

On a non-GAAP basis:

  • Total Operating Expenses decreased 7 percent, with all expense categories reflecting savings from our transformation and process improvement efforts. Cost of Sales margin improved by 0.4 percentage points driven primarily by manufacturing efficiencies, offset partially by product mix. R&D expenses decreased 13 percent driven by a payment in the first quarter of 2016 related to a third-party collaboration agreement, as well as lower spending required to support certain later-stage clinical programs. SG&A expenses decreased 6 percent due to the expiration of ENBREL residual royalty payments, offset partially by investments in product launches.

  • Operating Margin improved by 3 percentage points to 57.6 percent.

  • Tax Rate decreased 0.4 percentage points as changes in the geographic mix of earnings were offset partially by lower tax benefits from share-based compensation payments.

$Millions, except percentages
GAAP Non-GAAP
Q1’17 Q1’16 YOY Δ Q1’17 Q1’16 YOY Δ
Cost of Sales $996 $1,018 (2%) $682 $707 (4%)
% of product sales 19.2% 19.4% (0.2)pts 13.1% 13.5% (0.4) pts
Research & Development $769 $872 (12%) $748 $858 (13%)
% of product sales 14.8% 16.6% (1.8) pts 14.4% 16.4% (2) pts
Selling, General & Administrative $1,064 $1,203 (12%) $1,039 $1,103 (6%)
% of product sales 20.5% 23.0% (2.5) pts 20.0% 21.1% (1.1) pts
Other $44 $32 38% $0 $0 NM
TOTAL Operating Expenses $2,873 $3,125 (8%) $2,469 $2,668 (7%)
Operating Margin
operating income as a % of product sales 49.8% 45.8% 4 pts 57.6% 54.6% 3 pts
Tax Rate 15.8% 15.9% (0.1) pts 18.5% 18.9% (0.4) pts
NM: Not Meaningful
pts: percentage points

Cash Flow and Balance Sheet

  • The Company generated $2.2 billion of free cash flow in the first quarter of 2017 versus $1.8 billion in the first quarter of 2016 driven by the timing of tax payments and higher net income.

  • The Company’s second quarter 2017 dividend of $1.15 per share declared on March 7, 2017, will be paid on June 8, 2017, to all stockholders of record as of May 17, 2017.

  • During the first quarter, the Company repurchased 3.4 million shares of common stock at a total cost of $555 million. At the end of the first quarter, the Company had $3.5 billion remaining under its stock repurchase authorization.

$Billions, except shares Q1’17 Q1’16 YOY Δ
Operating Cash Flow $2.4 $1.9 $0.5
Capital Expenditures 0.2 0.2 0.0
Free Cash Flow 2.2 1.8 0.5
Dividends Paid 0.8 0.8 0.1
Share Repurchase 0.6 0.7 (0.1)
Avg. Diluted Shares (millions) 741 760 (19)
Cash and Investments 38.4 34.7 3.7
Debt Outstanding 34.1 34.3 (0.2)
Stockholders’ Equity 30.6 28.7 2.0
Note: Numbers may not add due to rounding

2017 Guidance

For the full year 2017, the Company now expects:

  • Total revenues in the range of $22.3 billion to $23.1 billion, unchanged from previous guidance.

  • On a GAAP basis, EPS in the range of $10.64 to $11.32 and a tax rate in the range of 16 percent to 18 percent.

    • Previously, the Company expected GAAP EPS in the range of $10.45 to $11.31. Tax rate guidance is unchanged.

  • On a non-GAAP basis, EPS in the range of $12.00 to $12.60 and a tax rate in the range of 18.5 percent to 19.5 percent.

    • Previously, the Company expected non-GAAP EPS in the range of $11.80 to $12.60. Tax rate guidance is unchanged.

  • Capital expenditures to be approximately $700 million.

First Quarter Product and Pipeline Update
Key development milestones:
Clinical Program Indication Projected Milestone
Repatha Hyperlipidemia Regulatory submissions (CV outcomes data)
KYPROLIS Relapsed or refractory  multiple myeloma Phase 3 study initiation with DARZALEX® Q2 ’17
XGEVA Prevention of SREs in multiple myeloma Regulatory reviews
EVENITY™ (romosozumab) Postmenopausal osteoporosis July 19, 2017, PDUFA target action date in U.S.

Active controlled Phase 3 fracture data Q2 2017*

Erenumab (AMG 334) Migraine prevention Regulatory submissions
ABP 215

(biosimilar bevacizumab)

Oncology Regulatory reviews

Sept. 14, 2017, BsUFA target action date in U.S.

ABP 980

(biosimilar trastuzumab)

Breast cancer U.S. regulatory submission
Trade name provisionally approved by FDA; CV = cardiovascular; SRE = skeletal-related event; PDUFA = Prescription Drug User Fee Act; BsUFA = Biosimilar User Fee Act; *Event driven study

The Company provided the following updates on selected product and pipeline programs:

Repatha

  • In February, the European Commission (EC) approved a new 420 mg single-dose delivery option for Repatha.

  • In March, positive Phase 3 data from a cardiovascular outcomes study and a cognitive function study were presented at the American College of Cardiology 66th Annual Scientific Session.

KYPROLIS

  • In February,  the Phase 3 ENDEAVOR study showed KYPROLIS and dexamethasone reduced the risk of death by 21 percent and extended overall survival by an additional 7.6 months compared to Velcade® (bortezomib) and dexamethasone in relapsed or refractory multiple myeloma patients.

XGEVA

  • In April, a supplemental Biologics License Application (sBLA) was submitted to the U.S. Food and Drug Administration (FDA) and an application for a variation to the marketing authorization was submitted to the European Medicines Agency (EMA) for the prevention of SREs in patients with multiple myeloma.

BLINCYTO

  • In March, FDA accepted the sBLA for priority review for BLINCYTO to include overall survival data from the Phase 3 TOWER study. The application also included new data supporting the treatment of patients with Philadelphia chromosome-positive relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

EVENITY

  • Primary analysis of an event driven active controlled Phase 3 fracture study (ARCH) in postmenopausal women with osteoporosis is expected in Q2 2017.

Erenumab

  • Regulatory submissions for migraine prevention are expected in Q2 2017.

CNP520

  • In February, Phase 3 enrollment commenced for CNP520, a small molecule beta-site amyloid precursor protein-cleaving enzyme-1 (BACE) inhibitor for the potential treatment of Alzheimer’s disease.

Parsabiv (etelcalcetide)

  • In February, FDA approved Parsabiv for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.

AMG 157/MEDI9929 (tezepelumab)

  • In February, tezepelumab demonstrated a significant reduction in the rate of asthma exacerbations compared to placebo over the 52-week treatment period in patients with severe asthma in a Phase 2b study.

AMGEVITA™ (biosimilar adalimumab)

  • In March, EC granted marketing authorization for AMGEVITA™ (biosimilar adalimumab) in all available indications. AMGEVITA is authorized for the treatment of certain inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); severe axial spondyloarthritis without radiographic evidence of AS; moderate-to-severe chronic plaque psoriasis; moderate-to-severe hidradenitis suppurativa; non-infectious intermediate, posterior and panuveitis; moderate-to-severe Crohn’s disease and moderate-to-severe ulcerative colitis. The EC also approved AMGEVITA for the treatment of certain pediatric inflammatory diseases, including moderate-to-severe Crohn’s disease (ages six and older), severe chronic plaque psoriasis (ages four and older), enthesitis-related arthritis (ages six and older) and polyarticular juvenile idiopathic arthritis (ages two and older).

ABP 980 (biosimilar trastuzumab)

  • In March, a Marketing Authorization Application was submitted to the EMA.

Erenumab and CNP520 are developed in collaboration with Novartis AG
EVENITY™ trade name is provisionally approved by FDA
EVENITY™ is developed in collaboration with UCB globally, as well as our joint venture partner Astellas in Japan
Tezepelumab is developed in collaboration with AstraZeneca
AMGEVITA™ is registered in the U.S. as AMJEVITA™
Velcade® is a registered trademark of Millennium Pharmaceuticals, Inc.

Non-GAAP Financial Measures

In this news release, management has presented its operating results for the first quarters of 2017 and 2016, in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and on a non-GAAP basis. In addition, management has presented its full year 2017 EPS and tax rate guidance in accordance with GAAP and on a non-GAAP basis. These non-GAAP financial measures are computed by excluding certain items related to acquisitions, restructuring and certain other items from the related GAAP financial measures. Reconciliations for these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the news release. Management has also presented Free Cash Flow (FCF), which is a non-GAAP financial measure, for the first quarters of 2017 and 2016. FCF is computed by subtracting capital expenditures from operating cash flow, each as determined in accordance with GAAP.

The Company believes that its presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. The Company uses certain non-GAAP financial measures to enhance an investor’s overall understanding of the financial performance and prospects for the future of the Company’s ongoing business activities by facilitating comparisons of results of ongoing business operations among current, past and future periods.  The Company believes that FCF provides a further measure of the Company’s liquidity.

The Company uses the non-GAAP financial measures set forth in the news release in connection with its own budgeting and financial planning internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. The non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Like up on FACEBOOK


Ebates Coupons and Cash Back



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




ALCOA CORPORATION REPORTS FIRST QUARTER 2017 RESULTS

ALCOA CORPORATION REPORTS FIRST QUARTER 2017 RESULTS

ALCOA CORPORATION REPORTS FIRST QUARTER 2017 RESULTS

ALCOA CORPORATION REPORTS FIRST QUARTER 2017 RESULTS

Company grew profits sequentially on stronger alumina and aluminum pricing

BUZ INVESTORS PRESS RELEASE Alcoa Corporation (NYSE: AA):

1Q 2017 Results1

  • Net income of $225 million, or $1.21 per share
  • Excluding special items, adjusted net income of $117 million, or $0.63 per share
  • Adjusted earnings before interest, tax, depreciation, and amortization (EBITDA), excluding special items of $533 million, up 59 percent sequentially driven by higher alumina and aluminum pricing
  • Revenue of $2.7 billion, up 5 percent sequentially, reflecting increased alumina and aluminum pricing
  • $804 million cash balance and $1.45 billion of debt, for net debt of $0.65 billion, as of March 31, 2017
  • Company continues to expect full-year 2017 adjusted EBITDA, excluding special items, between $2.1 billion and $2.3 billion2
$M, except per share amounts 1Q16 4Q16 1Q17
Revenue $ 2,129 $ 2,537 $ 2,655
Net (loss) income attributable to Alcoa Corporation $ (210 ) $ (125 ) $ 225
Earnings per share attributable to Alcoa Corporation $ (1.15 ) $ (0.68 ) $ 1.21
Adjusted (loss) income $ (114 ) $ 26 $ 117
Adjusted earnings per share $ (0.62 ) $ 0.14 $ 0.63
Adjusted EBITDA excluding special items $ 179 $ 335 $ 533

______________________________________________________________________

1 Prior to November 1, 2016, Alcoa Corporation’s financial statements were prepared on a carve-out basis, as the underlying operations of the Company were previously consolidated as part of Alcoa Corporation’s former parent company’s financial statements. Accordingly, the financial results of Alcoa Corporation for the quarter ended March 31, 2016 and for the month of October 2016 included in the quarter ended December 31, 2016 were also prepared on a carve-out basis. The carve-out financial statements of Alcoa Corporation are not necessarily indicative of Alcoa Corporation’s combined results of operations, financial position, and cash flows had it been a standalone company during the referenced periods. See the Consolidated Financial Statements included in the Company’s Form 10-K for the period ended December 31, 2016 filed with the United States Securities and Exchange Commission on March 15, 2017 for additional information.

2 Based on actual results for 1Q17, outlook for 2Q17 – 4Q17 at $1,900 LME, $305 API, and updated regional premiums and foreign currencies.




Alcoa Corporation

______________________________________________________________________

Alcoa Corporation (NYSE: AA), a global leader in bauxite, alumina, and aluminum products, today reported that first quarter 2017 profits grew sequentially on stronger alumina and aluminum pricing and that it maintained a solid cash position.

In addition, the Company reiterated its expectations of full-year 2017 adjusted EBITDA, excluding special items, between $2.1 billion and $2.3 billion, based on April 2017 market assumptions, and net performance of $50 million for the year.

“Alcoa is off to a strong start with our first full quarter as an independent company,” said Roy Harvey, Chief Executive Officer of Alcoa. “In our Bauxite segment, our third-party business remained strong and we continued to grow profits, while our Alumina and Aluminum segments captured the benefits of improved market pricing to increase earnings substantially.”

Harvey continued: “Over the last few months, we also remained focused on our strategic priorities. To reduce complexity, we consolidated our business units and administrative locations; we began to put our return seeking capital to work across our businesses to drive returns, and we continued to strengthen the balance sheet by maintaining a healthy level of cash on hand. As we look forward to the rest of 2017, we are well positioned to deliver value to our stockholders.”

In first quarter 2017, Alcoa reported net income of $225 million, or $1.21 per share. Results include $108 million of special items largely due to gains from the sale of the Yadkin Hydroelectric Project. First quarter 2017 results compare to a net loss of $125 million, or $(0.68) per share, in fourth quarter 2016, which included costs to streamline the portfolio.

Excluding the impact of special items, first quarter 2017 adjusted net income was $117 million, or $0.63 per share. In fourth quarter 2016, Alcoa’s adjusted net income was $26 million, or $0.14 per share, excluding special items.

Alcoa reported first quarter 2017 adjusted EBITDA excluding special items of $533 million, up 59 percent from $335 million in fourth quarter 2016. In first quarter 2017, Alcoa reported revenue of $2.7 billion, up 5 percent sequentially. Both revenue and adjusted EBITDA excluding special items increased on higher alumina and aluminum pricing.

In the first quarter, the Company’s cash from operations was $74 million and free cash flow was $3 million. Alcoa ended the first quarter of 2017 with cash on hand of $804 million after transferring the net proceeds received from the Yadkin sale to former parent Arconic Inc. according to terms of the separation agreement. The Company reported 19 days working capital.

In an ongoing effort to reduce complexity, in the first quarter Alcoa streamlined its business segments into three, focused on bauxite, alumina and aluminum. Earlier this month, the Company also announced a consolidation of its administrative locations.

Market Update

For 2017, Alcoa is projecting 2017 global aluminum demand growth of 4.5 to 5 percent over 2016. The Company continues to project relatively balanced global bauxite and alumina markets and a modest global aluminum surplus of 300 thousand to 700 thousand metric tons.

Conference Call

Alcoa will hold its quarterly conference call at 5:00 PM Eastern Daylight Time (EDT) on Monday, April 24, 2017 to present first quarter 2017 results and discuss its business and markets.

The call will be webcast via the Company’s homepage on www.alcoa.com. Presentation materials for the call will be available for viewing at approximately 4:15 PM EDT on April 24, 2017 on the same website. Call information and related details are available under the “Investors” section at www.alcoa.com.

Dissemination of Company Information

Alcoa intends to make future announcements regarding Company developments and financial performance through its website at www.alcoa.com.

About Alcoa Corporation

Alcoa (NYSE: AA) is a global industry leader in bauxite, alumina, and aluminum products, with a strong portfolio of value-added cast and rolled products and substantial energy assets. Alcoa is built on a foundation of strong values and operating excellence dating back nearly 130 years to the world-changing discovery that made aluminum an affordable and vital part of modern life. Since inventing the aluminum industry, and throughout our history, our talented Alcoans have followed on with breakthrough innovations and best practices that have led to efficiency, safety, sustainability, and stronger communities wherever we operate. Visit us online on www.alcoa.com, follow @Alcoa on Twitter and on Facebook at www.facebook.com/Alcoa.

We have included the above website addresses only as inactive textual references and do not intend these to be active links to such websites. Information contained on such websites or that can be accessed through such websites does not constitute a part of this press release.